Eli Lilly Expands Oncology Research Platform with Calytrix Bio Acquisition and Stipple Bio Partnership
Trendline

Eli Lilly Expands Oncology Research Platform with Calytrix Bio Acquisition and Stipple Bio Partnership

What's Happening? Eli Lilly (NYSE: LLY), a major U.S. pharmaceutical group, has announced a significant expansion of its oncology research platform through two strategic moves. The company has agreed to acquire Calytrix Bio, which will add rare blood cancer programs to its existing oncology pipeline
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.